Form 8-K - Current report:
SEC Accession No. 0001193125-25-005424
Filing Date
2025-01-14
Accepted
2025-01-13 18:54:26
Documents
15
Period of Report
2025-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d924755d8k.htm   iXBRL 8-K 27000
2 EX-99.1 d924755dex991.htm EX-99.1 18246
6 GRAPHIC g924755g0114012023422.jpg GRAPHIC 2585
  Complete submission text file 0001193125-25-005424.txt   178623

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20250113.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20250113_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20250113_pre.xml EX-101.PRE 11267
17 EXTRACTED XBRL INSTANCE DOCUMENT d924755d8k_htm.xml XML 3638
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 25527365
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)